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Immune checkpoint inhibitors are new therapeutic options for metastatic melanoma,
but few data are available in organ transplant recipient populations. Six French
patients, three men and three women, mean age 66 years (range 44-74), all kidney
transplant recipients, received ipilimumab (CTLA-4 inhibitor) for metastatic
melanoma. At diagnosis of advanced melanoma, immunosuppressive therapy had
been minimized in all but one. Adverse effects included one case of grade 1 diarrhea
and one of grade 1 pruritus. One patient had acute T cell-mediated rejection
confirmed by histology after the first injection of ipilimumab. After a median follow-
up of 4.5 (3-20) months, one patient achieved partial response, one had stable
disease, and four had disease progression. All the patients died, five from melanoma,
one from another cause. In this series and in the literature, ipilimumab proved to be
safe and possibly active. The acute rejection we encountered was probably related to
both a rapid, drastic reduction of immunosuppression and the use of ipilimumab.
Our safety data on ipilimumab contrast with the organ transplant rejections already
reported with PD-1 inhibitors. We consider that immunosuppression should not be






Titre abrégé Am. J. Transplant.
Identifiant
















Publié sur Okina (http://okina.univ-angers.fr)
